Regulacje i polityka gospodarcza · 20.12.2006

Prospective Grant of Exclusive License: Immunoconjugates Having High Binding Affinity

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent No. 7,081,518, issued July 25, 2006, entitled "Anti-Mesothelin Antibodies Having High-Affinity Binding" [E-139-1999/0-US-07]; European Patent Application No. 00937925.6, filed May 26, 2000, entitled "Immunoconjugates Having High Binding Affinity" [E-139-1999/ 0-EP-04]; Japanese Patent Application No. 2001-500670, filed May 26, 2000, entitled "Immunoconjugates Having High Binding Affinity" [E- 139-1999/0-JP-05]; Mexican Patent Application No. PA/a/2001/01195, filed May 26, 2000, entitled "Immunoconjugates Having High Binding Affinity" [E-139-1999/0-MX-06]; and Canadian Patent Application No. 2374398, filed May 26, 2000, entitled "Immunoconjugates Having High Binding Affinity" [E-139-1999/0-CA-03] to Cambridge Antibody Technology, Ltd., which has offices in Cambridge, United Kingdom. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory m